Immunomodulation with donor regulatory T cells armed with Fas-ligand alleviates graft-versus-host disease

Experimental Hematology

Volumn 41, Issue 10, 2013, Pages 903-911

  Yolcu, Esma S ^a   Kaminitz, Ayelet ^b   Mizrahi, Keren ^b   Ash, Shifra ^b   Yaniv, Isaac ^b   Stein, Jerry ^b   Shirwan, Haval ^a   Askenasy, Nadir ^b  

^a University of Louisville School of Medicine   (United States)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOMODULATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOID ORGAN; MESENTERY LYMPH NODE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOMODULATION; LYMPH NODES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, REGULATORY;

MURINAE; MUS;

EID: 84885852637     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.04.016     Document Type: Article

References (45)

1. Krenger W., Cooke K.R., Crawford J.M., et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996, 62:1278-1285.
2. + immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med 2002, 196:401-406.
3. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
4. Taylor P.A., Lees C.J., Blazar B.R. The infusion of exvivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
5. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
6. Ermann J., Hoffmann P., Edinger M., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105:2220-2226.
7. Trenado A., Charlotte F., Fisson S., et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus leukemia. J Clin Invest 2003, 112:1688-1696.
8. June C.H., Blazar B.R. Clinical application of expanded CD4+25+ cells. Semin Immunol 2006, 18:78-88.
9. Shatry A., Levy R.B. In situ activation and expansion of host tregs: A new approach to enhance donor chimerism and stable engraftment in major histocompatibility complex-matched allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:785-794.
10. Bayer A.L., Jones M., Chirinos J., et al. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood 2009, 113:733-743.
11. Yarkoni S., Prigozhina T.B., Slavin S., Askenasy N. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: exvivo selective depletion of host-reactive T cells and invivo therapy. Biol Blood Marrow Transplant 2012, 18:523-535.
12. Askenasy N., Yolcu E.S., Yaniv I., Shirwan H. Induction of tolerance using Fas ligand: A double-edged immunomodulator. Blood 2005, 105:1396-1404.
13. Yolcu E.S., Askenasy N., Singh N.P., Cherradi S.E., Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002, 17:795-808.
14. Yolcu E.S., Gu X., Lacelle C., et al. Induction of tolerance to cardiac allografts using donor splenocytes engineered to display on their surface an exogenous Fas ligand protein. J Immunol 2008, 181:931-939.
15. Yolcu E.S., Zhao H., Bandura-Morgan L., et al. Pancreatic islets engineered with SA-FasL protein establish robust localized tolerance by inducing regulatory T cells in mice. J Immunol 2011, 187:5901-5909.
16. Askenasy E.M., Shushlav Y., Sun Z., Shirwan H., Yolcu E.S., Askenasy N. Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs. Transplant Proc 2011, 43:3545-3548.
17. Kaminitz A., Yolcu E.S., Stein J., Yaniv I., Shirwan H., Askenasy N. Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun 2011, 37:39-47.
18. Kaminitz A., Askenasy N., Yolcu E.S. Immunomodulation with regulatory T cells and Fas-ligand ameliorate established inflammatory colitis. Gut 2013, 62:1228-1230.
19. Askenasy N., Kaminitz A., Yarkoni S. Mechanisms of T regulatory cell function. Autoimmun Rev 2008, 7:370-375.
20. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
21. Prigozhina T.B., Elkin G., Khitrin S., Slavin S. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation. Exp Hematol 2008, 36:1750-1759.
22. Askenasy N., Ash S., Askenasy E.M., Yaniv I., Stein J. Depletion of naive lymphocytes with Fas-ligand exvivo prevents GvHD without impairing T cell support of engraftment or GVT activity. Biol Blood Marrow Transplant 2013, 19:185-195.
23. Kaminitz A., Mizrahi K., Yaniv I., Farkas D.L., Stein J., Askenasy N. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice. J Autoimmun 2009, 33:83-91.
24. Ash S., Gigi V., Askenasy N., Fabian I., Stein J., Yaniv I. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD. Cancer Immunol Immunother 2009, 58:2073-2084.
25. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 2005, 22:329-341.
26. Graca L., Cobbold S.P., Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002, 195:1641-1646.
27. Sanchez-Fueyo A., Weber M., Domenig C., et al. Tracking the immunoregulatory mechanisms active during allograft tolerance. J Immunol 2002, 168:2274-2281.
28. Schmidt-Lucke C., Aicher A., Romagnani P., et al. Specific recruitment of CD4+CD25++ regulatory T cells into the allograft in heart transplant recipients. Am J Physiol Heart Circ Physiol 2007, 292:H2425-H2431.
29. Barthlott T., Kassiotis G., Stockinger B. T cell regulation as a side effect of homeostasis and competition. J Exp Med 2003, 197:451-460.
30. Zhang H., Chua K.S., Guimond M., et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005, 11:1238-1243.
31. Yaniv I., Ash S., Farkas D.L., Askenasy N., Stein J. Consideration of strategies for hematopoietic cell transplantation. J Autoimmun 2009, 33:255-259.
32. Kaminitz A., Askenasy E.M., Yaniv I., Stein J., Askenasy N. Apoptosis of purified CD4+ T cell subsets is dominated by cytokine deprivation and absence of other cells in new onset diabetic NOD mice. PLoS One 2010, 5:e15684.
33. Kaminitz A., Yolcu E.S., Askenasy E.M., et al. Effector and naturally occurring regulatory T cells display no abnormalities in activation induced cell death in NOD mice. PLoS One 2011, 6:e21630.
34. Ash S., Stein J., Askenasy N., Yaniv I. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation. Br J Cancer 2010, 103:1597-1605.
35. Zelenay S., Lopes-Carvalho T., Caramalho I., Moraes-Fontes M.F., Rebelo M., Demengeot J. Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U S A 2005, 102:4091-4096.
36. Komatsu N., Mariotti-Ferrandiz M.E., Wang Y., Malissen B., Waldmann H., Hori S. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci U S A 2009, 106:1903-1908.
37. Iwasaki T., Hamano T., Saheki K., et al. Effect of graft-versus-host disease (GVHD) on host hematopoietic progenitor cells is mediated by Fas-Fas ligand interactions but this does not explain the effect of GVHD on donor cells. Cell Immunol 1999, 197:30-38.
38. Marks L., Altman N.H., Podack E.R., Levy R.B. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation 2004, 77:804-812.
39. Kim S., Kim K.A., Hwang D.Y., et al. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J Immunol 2000, 164:2931-2936.
40. van Den Brink M.R., Moore E., Horndasch K.J., et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol 2000, 164:469-480.
41. van den Brink M.R., Moore E., Horndasch K.J., Crawford J.M., Murphy G.F., Burakoff S.J. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation 2000, 70:184-191.
42. Yolcu E.S., Ash S., Kaminitz A., Sagiv Y., Askenasy N., Yarkoni S. Apoptosis as a mechanism of T-regulatory cell homeostasis and suppression. Immunol Cell Biol 2008, 86:650-658.
43. Kaminitz A., Mizrahi K., Yaniv I., Stein J., Askenasy N. Immunosuppressive therapy exacerbates autoimmunity in NOD mice and diminishes the protective activity of regulatory T cells. J Autoimmun 2010, 35:145-152.
44. Brunstein C.G., Miller J.S., Cao Q., et al. Infusion of exvivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
45. Di Ianni M., Falzetti F., Carotti A., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.